These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 3210014)

  • 21. Quantifying iron deposition within the substantia nigra of Parkinson's disease by quantitative susceptibility mapping.
    An H; Zeng X; Niu T; Li G; Yang J; Zheng L; Zhou W; Liu H; Zhang M; Huang D; Li J
    J Neurol Sci; 2018 Mar; 386():46-52. PubMed ID: 29406966
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The whole-brain pattern of magnetic susceptibility perturbations in Parkinson's disease.
    Acosta-Cabronero J; Cardenas-Blanco A; Betts MJ; Butryn M; Valdes-Herrera JP; Galazky I; Nestor PJ
    Brain; 2017 Jan; 140(1):118-131. PubMed ID: 27836833
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Potential sources of increased iron in the substantia nigra of parkinsonian patients.
    Gerlach M; Double KL; Youdim MB; Riederer P
    J Neural Transm Suppl; 2006; (70):133-42. PubMed ID: 17017520
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Decreased ferritin levels in brain in Parkinson's disease.
    Dexter DT; Carayon A; Vidailhet M; Ruberg M; Agid F; Agid Y; Lees AJ; Wells FR; Jenner P; Marsden CD
    J Neurochem; 1990 Jul; 55(1):16-20. PubMed ID: 2355217
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lack of up-regulation of ferritin is associated with sustained iron regulatory protein-1 binding activity in the substantia nigra of patients with Parkinson's disease.
    Faucheux BA; Martin ME; Beaumont C; Hunot S; Hauw JJ; Agid Y; Hirsch EC
    J Neurochem; 2002 Oct; 83(2):320-30. PubMed ID: 12423242
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Modulation effect of substantia nigra iron deposition and functional connectivity on putamen glucose metabolism in Parkinson's disease.
    Zang Z; Song T; Li J; Yan S; Nie B; Mei S; Ma J; Yang Y; Shan B; Zhang Y; Lu J
    Hum Brain Mapp; 2022 Aug; 43(12):3735-3744. PubMed ID: 35471638
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mössbauer spectroscopy and ELISA studies reveal differences between Parkinson's disease and control substantia nigra.
    Galazka-Friedman J; Bauminger ER; Koziorowski D; Friedman A
    Biochim Biophys Acta; 2004 Mar; 1688(2):130-6. PubMed ID: 14990343
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Detection of nitrosyl complexes in human substantia nigra, in relation to Parkinson's disease.
    Shergill JK; Cammack R; Cooper CE; Cooper JM; Mann VM; Schapira AH
    Biochem Biophys Res Commun; 1996 Nov; 228(2):298-305. PubMed ID: 8920909
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease.
    Dexter DT; Carter CJ; Wells FR; Javoy-Agid F; Agid Y; Lees A; Jenner P; Marsden CD
    J Neurochem; 1989 Feb; 52(2):381-9. PubMed ID: 2911023
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Iron in the basal ganglia in Parkinson's disease. An in vitro study using extended X-ray absorption fine structure and cryo-electron microscopy.
    Griffiths PD; Dobson BR; Jones GR; Clarke DT
    Brain; 1999 Apr; 122 ( Pt 4)():667-73. PubMed ID: 10219780
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differential Alterations in Metabolism and Proteolysis-Related Proteins in Human Parkinson's Disease Substantia Nigra.
    Grünblatt E; Ruder J; Monoranu CM; Riederer P; Youdim MB; Mandel SA
    Neurotox Res; 2018 Apr; 33(3):560-568. PubMed ID: 29218503
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Magnetic resonance correlation of iron content with neuromelanin in the substantia nigra of early-stage Parkinson's disease.
    Reimão S; Ferreira S; Nunes RG; Pita Lobo P; Neutel D; Abreu D; Gonçalves N; Campos J; Ferreira JJ
    Eur J Neurol; 2016 Feb; 23(2):368-74. PubMed ID: 26518135
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vivo imaging of neuromelanin in Parkinson's disease using 18F-AV-1451 PET.
    Hansen AK; Knudsen K; Lillethorup TP; Landau AM; Parbo P; Fedorova T; Audrain H; Bender D; Østergaard K; Brooks DJ; Borghammer P
    Brain; 2016 Jul; 139(Pt 7):2039-49. PubMed ID: 27190023
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Unaltered aconitase activity, but decreased complex I activity in substantia nigra pars compacta of patients with Parkinson's disease.
    Janetzky B; Hauck S; Youdim MB; Riederer P; Jellinger K; Pantucek F; Zöchling R; Boissl KW; Reichmann H
    Neurosci Lett; 1994 Mar; 169(1-2):126-8. PubMed ID: 8047266
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [3H]Nitrendipine binding sites are decreased in the substantia nigra and striatum of the brain from patients with Parkinson's disease.
    Nishino N; Noguchi-Kuno SA; Sugiyama T; Tanaka C
    Brain Res; 1986 Jul; 377(1):186-9. PubMed ID: 2942224
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Mechanism of α-lipoic acid promoting iron efflux in substantia nigra cells of Parkinson's disease rats].
    Cai T; Wei C; Zhai S; Tai S; Zhang C; Jiao L
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2018 Jan; 34(1):35-40. PubMed ID: 29595455
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quantitative Susceptibility Mapping in Parkinson's Disease.
    Langkammer C; Pirpamer L; Seiler S; Deistung A; Schweser F; Franthal S; Homayoon N; Katschnig-Winter P; Koegl-Wallner M; Pendl T; Stoegerer EM; Wenzel K; Fazekas F; Ropele S; Reichenbach JR; Schmidt R; Schwingenschuh P
    PLoS One; 2016; 11(9):e0162460. PubMed ID: 27598250
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The density of [125I]-transferrin binding sites on perikarya of melanized neurons of the substantia nigra is decreased in Parkinson's disease.
    Faucheux BA; Hauw JJ; Agid Y; Hirsch EC
    Brain Res; 1997 Feb; 749(1):170-4. PubMed ID: 9070646
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adenosine A(2A) receptor mRNA expression in Parkinson's disease.
    Hurley MJ; Mash DC; Jenner P
    Neurosci Lett; 2000 Sep; 291(1):54-8. PubMed ID: 10962152
    [TBL] [Abstract][Full Text] [Related]  

  • 40. p53 protein, interferon-gamma, and NF-kappaB levels are elevated in the parkinsonian brain.
    Mogi M; Kondo T; Mizuno Y; Nagatsu T
    Neurosci Lett; 2007 Feb; 414(1):94-7. PubMed ID: 17196747
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.